Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 5
2000 7
2001 5
2002 11
2003 4
2004 4
2005 1
2006 2
2007 6
2008 12
2009 18
2010 31
2011 36
2012 39
2013 56
2014 50
2015 74
2016 73
2017 70
2018 79
2019 80
2020 79
2021 106
2022 71
2023 76
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

910 results

Results by year

Filters applied: . Clear all
Page 1
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Krönke J, et al. Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29. Science. 2014. PMID: 24292625 Free PMC article.
Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown. Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription fac …
Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown. …
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
Stanulla M, Cavé H, Moorman AV. Stanulla M, et al. Blood. 2020 Jan 23;135(4):252-260. doi: 10.1182/blood.2019000813. Blood. 2020. PMID: 31821407 Free PMC article. Review.
Here, we review the advances that have shed light on the role of IKZF1 aberration as prognostic factor in pediatric ALL and summarize emerging concepts in this field. ...
Here, we review the advances that have shed light on the role of IKZF1 aberration as prognostic factor in pediatric ALL and summarize …
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer.
Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, Connelly JP, Lim SA, Saravia J, Kc A, Pruett-Miller SM, Chi H. Zhou P, et al. Nature. 2023 Dec;624(7990):154-163. doi: 10.1038/s41586-023-06733-x. Epub 2023 Nov 15. Nature. 2023. PMID: 37968405 Free PMC article.
Collectively, our study reveals that promoting the exit from quiescence of T(pex) cells and enriching the proliferative T(ex) cell state act as key modalities for antitumour effects and provides a systemic framework to integrate cell fate regulomes and reprogrammable functional d …
Collectively, our study reveals that promoting the exit from quiescence of T(pex) cells and enriching the proliferative T(ex) cell state act …
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.
Bonazzi S, d'Hennezel E, Beckwith REJ, Xu L, Fazal A, Magracheva A, Ramesh R, Cernijenko A, Antonakos B, Bhang HC, Caro RG, Cobb JS, Ornelas E, Ma X, Wartchow CA, Clifton MC, Forseth RR, Fortnam BH, Lu H, Csibi A, Tullai J, Carbonneau S, Thomsen NM, Larrow J, Chie-Leon B, Hainzl D, Gu Y, Lu D, Meyer MJ, Alexander D, Kinyamu-Akunda J, Sabatos-Peyton CA, Dales NA, Zécri FJ, Jain RK, Shulok J, Wang YK, Briner K, Porter JA, Tallarico JA, Engelman JA, Dranoff G, Bradner JE, Visser M, Solomon JM. Bonazzi S, et al. Cell Chem Biol. 2023 Mar 16;30(3):235-247.e12. doi: 10.1016/j.chembiol.2023.02.005. Epub 2023 Mar 1. Cell Chem Biol. 2023. PMID: 36863346 Free article.
Here we report the discovery of NVP-DKY709, a selective molecular glue degrader of IKZF2 that spares IKZF1/3. We describe the recruitment-guided medicinal chemistry campaign leading to NVP-DKY709 that redirected the degradation selectivity of cereblon (CRBN) binders from …
Here we report the discovery of NVP-DKY709, a selective molecular glue degrader of IKZF2 that spares IKZF1/3. We describe the recruit …
IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group. Stanulla M, et al. J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2. J Clin Oncol. 2018. PMID: 29498923 Free article.
Results IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1(plus). The IKZF1(plus) group comprised 6% of patients with BCP ALL, wi …
Results IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the …
Molecular markers in ALL: Clinical implications.
Kimura S, Mullighan CG. Kimura S, et al. Best Pract Res Clin Haematol. 2020 Sep;33(3):101193. doi: 10.1016/j.beha.2020.101193. Epub 2020 Jun 7. Best Pract Res Clin Haematol. 2020. PMID: 33038982 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a main cause of death in children despite recent improvements in cure rates. ...
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a main cause of death in children despite recent i …
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR; Children's Oncology Group. Mullighan CG, et al. N Engl J Med. 2009 Jan 29;360(5):470-80. doi: 10.1056/NEJMoa0808253. Epub 2009 Jan 7. N Engl J Med. 2009. PMID: 19129520 Free PMC article.
This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS. The gene-expression signature of the group of patients with a poor outcome revealed increased expression of hematopoietic stem-cell genes and redu …
This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS. The ge …
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T, Mukerji R, Reddy PJ, Powers J, Sanchez Garcia de Los Rios M, Ye J, Barrientos Risso C, Tsai D, Pardo G, Notti RQ, Pardo A, Affer M, Nawaratne V, Totiger TM, Pena-Velasquez C, Rhodes JM, Zelenetz AD, Alencar A, Roeker LE, Mehta S, Garippa R, Linley A, Soni RK, Skånland SS, Brown RJ, Mato AR, Hansen GM, Abdel-Wahab O, Taylor J. Montoya S, et al. Science. 2024 Feb 2;383(6682):eadi5798. doi: 10.1126/science.adi5798. Epub 2024 Feb 2. Science. 2024. PMID: 38301010 Free PMC article.
Here we identify inhibitor resistance mutations in BTK with distinct enzymatic activities, including some that impair BTK enzymatic activity while imparting novel protein-protein interactions that sustain B cell receptor (BCR) signaling. Furthermore, we describe a clinical-stage …
Here we identify inhibitor resistance mutations in BTK with distinct enzymatic activities, including some that impair BTK enzymatic activity …
Advances in germline predisposition to acute leukaemias and myeloid neoplasms.
Klco JM, Mullighan CG. Klco JM, et al. Nat Rev Cancer. 2021 Feb;21(2):122-137. doi: 10.1038/s41568-020-00315-z. Epub 2020 Dec 16. Nat Rev Cancer. 2021. PMID: 33328584 Free PMC article. Review.
Although much work has focused on the elucidation of somatic alterations that drive the development of acute leukaemias and other haematopoietic diseases, it has become increasingly recognized that germline mutations are common in many of these neoplasms. In this Review, w …
Although much work has focused on the elucidation of somatic alterations that drive the development of acute leukaemias and other haematopoi …
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Foà R, et al. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or both [i.e., IKZF1 (plus)]). ...
At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patien …
910 results